REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Feb 16, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-02-14

Reporting Person: McCorkle Douglas S (VP Controller and Asst Treasur)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-14	Common Stock	M	500	$21.92	Acquired	500	Direct
2012-02-14	Common Stock	S	500	$110.5	Disposed	0	Direct
2012-02-14	Common Stock	M	4062	$21.92	Acquired	4062	Direct
2012-02-14	Common Stock	S	4062	$109.01	Disposed	0	Direct
2012-02-14	Common Stock	M	15438	$21.92	Acquired	15438	Direct
2012-02-14	Common Stock	F	3048	$111.01	Disposed	12390	Direct
2012-02-14	Common Stock	F	4807	$111.01	Disposed	7583	Direct
2012-02-14	Common Stock	M	15000	$16.8	Acquired	22583	Direct
2012-02-14	Common Stock	F	2269	$111.01	Disposed	20314	Direct
2012-02-14	Common Stock	F	5864	$111.01	Disposed	14450	Direct
2012-02-15	Common Stock	S	9097	$111.08	Disposed	5353	Direct
2012-02-16	Common Stock	S	5353	$107.5	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-02-14	Incentive Stock Option (right to buy)	$21.92	M	500	Disposed	2017-12-17	Common Stock (500)	Direct
2012-02-14	Incentive Stock Option (right to buy)	$21.92	M	4062	Disposed	2017-12-17	Common Stock (4062)	Direct
2012-02-14	Non-Qualified Stock Option (right to buy)	$16.8	M	15000	Disposed	2018-12-17	Common Stock (15000)	Direct
2012-02-14	Non-Qualified Stock Option (right to buy)	$21.92	M	15438	Disposed	2017-12-17	Common Stock (15438)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4264	Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 9,097 shares of Company stock on February 15, 2012 at prices ranging from $111.00 to $111.38 . Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 15, 2012 at each separate price.

F2: Represents volume-weighted average price of sales of 5,353 shares of Company stock on February 16, 2012 at prices ranging from $107.50 to $107.51 . Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 16, 2012 at each separate price.

F3: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F4: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.